To the Editor:
Solid tumors require an adequate supply of blood vessels to survive, grow, and metastasize. [1] [2] [3] New blood vessels that nourish growing tumors form by angiogenesis. Drugs shown to have antiangiogenic activity are currently in clinical cancer trials. 4 To date, anti-angiogenic drugs have had mixed success in clinical application. Many new compounds may need to be tested to identify drugs capable of treating a wide range of tumors. The ideal assay for screening new compounds should involve blood vessels growing in their natural environment, such as a whole living organism, yet be amenable to rapid analysis. No current assays provide such a unique combination. We describe here an assay using the zebrafish (Danio rerio) that provides the relevance of an in vivo environment as well as the potential for high throughput drug screening.
The zebrafish has become a well accepted model for studies of vertebrate developmental biology. The vascular system has been well described and shown to be highly conserved in the zebrafish. 5, 6 Many zebrafish blood vessels form by angiogenic sprouting and appear to require the same proteins that are necessary for blood vessel growth in mammals. In addition, anti-angiogenic compounds, such as PTK787/ZK222584 and SU5416, have been shown to affect the formation of zebrafish blood vessels. 7, 8 Current methods of visualizing blood vessels in the zebrafish include whole mount in situ hybridization, 9,10 detection of endogenous alkaline phosphatase activity, 8 and microangiography. 11 The first two methods are time consuming and involve fixation of embryos and larvae prior to analysis. Microangiography is also labor intensive and only useful for visualization of patent blood vessels in a complete circulatory system. Transgenic zebrafish with fluorescent blood vessels 12, 13 represent a less labor-intensive way of visualizing blood vessels in the zebrafish. We have generated a transgenic line with fluorescent blood vessels by driving expression of a green reef coral fluorescent protein (G-RCFP 14 ) with a promoter for the vascular endothelial growth factor receptor 2 gene (VEGFR2, also referred to as Flk-1 or KDR).
VEGFR2 is one of several receptors for VEGF family members in humans and is expressed specifically in blood vessels. 15 Several zebrafish VEGFR2 cDNAs have been cloned and their expression pattern described. 7, 9, 10, 16 We used a 6.5-KB genomic fragment 5Ј to the VEGFR2 initiation codon to drive G-RCFP expression specifically in zebrafish blood vessels. Hereafter, the stable transgenic line generated is referred to as TG(VEGFR2:G-RCFP), using standard zebrafish nomenclature. The expression pattern of G-RCFP in TG(VEGFR2:G-RCFP) embryos mirrored that of VEGFR2 in situ hybridization (not shown). Please see Figure I , available at http:// atvb.ahajournals.org, for detailed fluorescent expression in TG(VEGFR2:G-RCFP) embryos.
The bright, consistent fluorescence of angiogenic blood vessels in TG(VEGFR2:G-RCFP) zebrafish embryos suggested that they could provide an ideal tool for testing angiogenesis drugs. Jain et al 17 described several factors that are important for the design of an optimal angiogenesis assay, including ease of experimentation, cost-effectiveness, rapidity, reproducibility, and ability to quantify vessel formation. Pairs of adult zebrafish produce thousands of eggs routinely and are relatively inexpensive to maintain, thus fulfilling the first two criteria.
To test the utility of the TG(VEGFR2:G-RCFP) line for angiogenesis drug screening, we subjected embryos to compounds known to have anti-angiogenic activity, including SU5416 18, 19 and SU6668, 20 two indolinone-based small molecules demonstrated to inhibit VEGF-induced vascular endothelial cell proliferation in vitro. Furthermore, SU5416 and SU6668 have been reported to inhibit the formation of metastases and microvessel formation and increase apoptosis of both tumor cells and tumor endothelial cells in mouse xenograft models. 21 SU5416 is believed to specifically target VEGF receptors, 18, 22 while SU6668 inhibits the basic fibroblast growth factor receptor and the platelet-derived growth factor receptor in addition to the VEGF receptors. 20 Zebrafish embryos from the TG(VEGFR2:G-RCFP) line were incubated overnight with SU5416 and SU6668, beginning when embryos were at the 13-somite stage (approximately 15 hours post fertilization [hpf]), before angiogenic sprouting of intersegmental and head vessels had begun. As shown in parts A through C of the Figure, both compounds completely blocked intersegmental vessel formation, while preserving fluorescence in the dorsal aorta, caudal artery, caudal veins, and major cranial vessels. In addition, blood vessels in the head that form by angiogenesis were not observed in treated embryos. Treated embryos also exhibited an enlarged pericardial cavity and evidence of blood pooling in the ventral tail. These findings are reminiscent of the phenotype observed following knockdown of VEGF-A in the zebrafish by antisense morpholino, 23 suggesting that these effects result from lack of a functioning vascular system rather than nonspecific toxicity. The concentrations of the compounds required to see these effects (10 mol/L for SU5416 and 15 mol/L for SU6668) are similar to the plasma level of SU5416 (5 mol/L) in patients treated in clinical trials. 4, 19 For each compound, 136 embryos were treated in several separate experiments, and all exhibited the phenotype shown in the Figure. To determine whether angiogenesis could resume after the embryos are removed from the compounds, embryos were allowed to A through C, Zebrafish embryos at 30 hpf; scale barϭ100 m. Yellow arrows indicate the dorsal aorta and red arrows indicate the caudal vein. A, Untreated embryo. An intersegmental vessel is indicated by the white arrow. B, Embryo treated overnight with 10 mol/L SU5416. No intersegmental vessels were observed. Autofluorescence due to SU5416 is concentrated in the yolk (arrowhead). C, Embryo treated overnight with 15 mol/L SU6668. No intersegmental vessels were observed. Autofluorescence due to SU6668 is concentrated in the yolk (arrowhead). D, Larva at 5 dpf, treated overnight with 15 mol/L SU6668 and allowed to recover for 3 days in fresh water. Intersegmental vessels are reforming. Examples of vessels that are migrating abnormally are indicated by the white arrows. recover in fresh water for 24 to 72 hours after application of compounds. We found that blood vessels do begin to sprout again from the dorsal aorta, but they often appear irregular in shape and position, when compared with untreated embryos, as shown in part D of the Figure. Intersegmental blood vessel patterning is dependent on signals originating from the somites. 24 While the somites in drug-treated embryos appeared normal, it is possible that molecules required for correct patterning of intersegmental vessels are not present at this later stage of development. Alternatively, drug treatment may affect expression of repulsive signals in the somites. Please see Figure II , available at http://atvb.ahajournals.org, for further experiments performed with these compounds.
In conclusion, the TG(VEGFR2:G-RCFP) fish could form the basis of an in vivo assay for angiogenesis inhibitors. Zebrafish embryos arrayed in 96-well plates and subjected to a large number of different compounds have been used successfully to identify compounds that interfere with early development in the zebrafish. 25 The dramatic changes in G-RCFP fluorescence that we observed after application of angiogenesis inhibitors should be easily quantifiable, and with new developments in microplate reader capabilities, it should be possible to develop a system for rapidly screening thousands of molecules per week for anti-angiogenic activity. Given the importance of this area for the identification of new drugs for cancer treatment, a simple, potentially quantitative, relatively inexpensive assay, such as that described in this letter, would be a major addition to the field of angiogenesis drug screening.
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Confirmation of the Microsomal Triglyceride Transfer Protein Genetic Effect on Lipids in Young African American Men From the CARDIA Study
To the Editor:
We previously studied the association between the Ϫ493 G/T polymorphism of the microsomal triglyceride transfer protein (MTP) gene and the lipid profile in young African American men from the CARDIA cohort. 1 The total cholesterol and LDL cholesterol (LDL-C) levels were significantly higher in the TT genotype in the first 4 consecutive measures between 1985 and 1993, but not in the 5th measure in 1996. We analyzed the new data measured in 2001 from the same cohort to test whether the nonsignificant result in the 5th measure is due to diminished genetic effect with age or random variation of data.
The results from analysis of the 6th measure in 2001 showed a significant genetic effect, confirming the influence of the MTP promoter polymorphism in this cohort. Total cholesterol, LDL-C, and nonHDL-C (ie, total cholesterol minus HDL-C) in the TT genotype are higher than in the other two genotypes in the year 2001 data, which is consistent with results from the 1st to 4th measures (Table) . The present results suggested that the nonsignificant results in the 5th data were more likely to be due to random variation. The TT genotype was associated with higher levels (mg/dL) of total cholesterol ranging from 2 to 19, LDL-C ranging from 9 to 17 (no difference in the 5th measure), and nonHDL-C ranging from 2 to 19 (Table) . Longitudinal analysis by the generalized estimating equation (GEE) model 2, 3 revealed no evidence of interaction between genotype and time: the coefficients were Ϫ0.41 (Pϭ0.19) for total cholesterol, Ϫ0.04 (Pϭ0.71) for HDL-C, and Ϫ0.38 (Pϭ0.22) for nonHDL-C. Based on the GEE model, the TT genotype had average higher levels of total cholesterol, LDL-C, and nonHDL-C than the (GGϩGT) group, by 11.48 (Pϭ0.04), 9.98 (Pϭ0.049), and 12.40 (Pϭ0.03), respectively, during the 15-year follow-up. HDL-C levels were not significantly different among the three genotypes in all 6 examinations.
However, the studies of the Ϫ493 G/T MTP polymorphism have yielded conflicting results. The Framingham Offspring Study, 4 in which the participants were primarily middle-aged (the mean age of 52 years) whites, reported no significant association, although they found that the TT genotype was associated with higher cholesterol levels. In contrast, studies of the Northern European men reported an opposite result to our finding, with the T allele associated with lower levels of total cholesterol, LDL-C, and triglycerides. 5, 6 A functional study has shown that the T allele has 2-fold higher transcriptional activity than the G allele, 5 which is hard to reconcile with the opposite effects of the TT genotype observed in Northern European men. It is possible that the MTP gene interacts with other genes or environment leading to a complex situation. However, more studies are necessary to address these intriguing findings.
In summary, analysis of the 15-year data reveals a significant genetic effect of the MTP promoter polymorphism on lipids. The genotypic effect did not change over time. More studies are needed to address the conflicting observations between blacks and whites, as well as between Americans and Northern Europeans. 
Suh-Hang Hank
Possible Impact of Tetrahydrobiopterin and Sepiapterin on Endothelial Dysfunction
To the Editor: Vasquez-Vivar et al 1 reported on diminished tetrahydrobiopterin (BH 4 ) concentrations in vessels from hypercholesterolemic rabbits. This is an interesting finding because both in serum and urine from patients with coronary artery diseases and hypercholesterolemia, total plasma biopterin concentrations were found to be unchanged 2 (unpublished data, 2002). However, total biopterin represents the sum of BH 4 , 7,8-dihydrobipterin (BH 2 ), and fully oxidized biopterin, and one cannot exclude possible the effect of either reduced BH 4 or increased BH 2 concentrations on the endothelial dysfunction in these patients. In normal plasma, almost all biopterin (Ͼ95%) is present as BH 4 , and measurement of biologically active tetrahydro-derivative seems to be essential. Differential oxidation with iodine and subsequent high-pressure liquid chromatography (HPLC), according to Fukushima and Nixon, 3 is a simple method to measure different oxidation forms of biopterin. In this method, under acidic conditions, BH 4 and BH 2 are oxidized to biopterin, while under basic conditions, only BH 2 is oxidized to biopterin, and BH 4 undergoes a side-chain cleavage to form the blue fluorescing pterin. The difference in biopterin content between the two oxidations represents the actual BH 4 levels. HPLC separation of biopterin from pterin and isoxanthopterin is essential for the correct interpretation.
Another important finding of Vasquez-Vivar et al 1 is the observation that supplementation with sepiapterin, an intermediate in the salvage pathway of BH 4 , worsens responses to endotheliumdependent agonists Ach and A23187 and that sepiapterin in high concentrations uncouples purified endothelial NO synthase (eNOS) and leads to generation of superoxide O 2 Ϫ . Recently, it has been shown that BH 2 and sepiapterin inhibit NOS in vitro by displacing the prebound BH 4 with Ͼ80% efficiency. 4 BH 2 and sepiapterin are metabolites that accumulate in patients with variants of BH 4 deficiency, and it has been suggested that they may potentate the superoxide formation during the uncoupled reaction of NOS. 5 The GG and GT genotypes were pooled. GEE model is adjusted for center, baseline age, and time-dependent body mass index.
production was found to be significantly reduced in the brain in these patients. 7 Particularly, patients with sepiapterin reductase deficiency, in which both BH 2 and sepiapterin accumulate in the brain, have extremely low levels of nitrate and nitrite (end products of NO) in cerebrospinal fluid (Figure) and low-dose treatment with BH 4 (2.5 to 5.0 mg/kg) was not efficient to restore the brain's NO production. Thus, both the oxidation of BH 4 to BH 2 and sepiapterin formation promote uncoupling of the NOS reaction and stimulate superoxide and peroxynitrite production. Although patients with BH 4 deficiency show no cardiovascular problems, one can speculate that, in patients with hypercholesterolemia and other diseases presenting with endothelial dysfunction, a similar situation occurs. Sepiapterin is first reduced in endothelial vessels to BH 2 by sepiapterin reductase, but the capacity of dihydrofolate reductase to reduce BH 2 to BH 4 may be to low, resulting in formation of toxic metabolites. Incubating the vessels with methotrexate, an inhibitor of dihydrofolate reductase, may bring additional information on how sepiapterin and BH 2 promote the superoxide formation.
A number of studies documented that pro-inflammatory cytokines increase BH 4 formation in cultured vascular endothelial cells. 8 Another factor which may influence vascular BH 4 levels is vitamin C. It has been shown recently that long-term treatment with vitamin C decreases BH 2 levels and increase BH 4 levels in aortas of apolipoprotein-deficient mice. 9 Simultaneous application of vitamin C ϩ E, as suggested in patients with sepiapterin reductase deficiency in order to improve the efficiency of the BH 4 therapy, needs further investigation.
Nenad Blau Beat Thöny Division of Clinical Chemistry and Biochemistry, University
Children's Hospital, Zurich, Switzerland
In Response:
Inadequate tetrahydrobiopterin (BH 4 ) concentration has been linked to impaired endothelial NO synthase (eNOS) activity and to loss of endothelial function in vascular conditions such as hypercholesterolemia. Blau and Thöny correctly contend that despite the critical importance of BH 4 in NO formation from eNOS, patients with BH 4 deficiency typically show no evidence of vascular disease. Studies that have evaluated the effects of BH 4 supplementation have further observed divergent effects in animal models as well as in humans, with some studies reporting beneficial or no effects and a few reporting actual worsening of vascular function. 1 We have recently presented an alternative hypothesis that may reconcile these apparently contradictory findings. This is that the relative concentrations of fully reduced (BH 4 ) and oxidized forms of tetrahydrobiopterin (BH 2 ), rather than the absolute concentration of BH 4 , are what governs the nature of products generated from eNOS. 2 At low BH 4 or high BH 2 (7,8-dihydrobiopterin or sepiapterin) levels, eNOS generates superoxide that is not inhibited by saturating L-arginine or ascorbate. 2 In addition, experimental BH 4 deficiency (such as that induced by treatment with 2,4-diamino-6-hydroxy-pyrimidine and N-acetylserotonin, a GTP cyclohydrolase-I and sepiapterin reductase inhibitor, respectively) shows that supplementation with sepiapterin in the presence of N-acetylserotonin causes further increases in superoxide production by endothelial cells. This indicates that the BH 4 /BH 2 ratio controls superoxide formation in the endothelium and may represent a physiologically relevant mechanism to regulate eNOS products.
Based on our study, it appears that BH 4 homeostasis in atherosclerotic vascular tissue is complex. While the tissue retains the ability to generate BH 4 from sepiapterin, this activity does not translate to improvements in vascular relaxation. Cotreatment with N-acetylcysteine augments BH 4 concentrations beyond normal levels and yet did not ameliorate vascular function. This result indicates that BH 4 metabolism is altered in experimental atherosclerosis, and that mere supplementation with sepiapterin, an oxidized precursor of BH 4 , alone or with antioxidants does not translate to therapeutic benefits. The mechanisms involved in the regulation of BH 4 levels in the vascular wall are not known. Likewise, it is unclear how ascorbate may influence the BH 4 /BH 2 ratio in the endothelium. It has been shown that chemical reduction of 7,8-BH 2 to generate BH 4 is not a mechanism by which ascorbate alters BH 4 /BH 2 ratio. 3 Also, ascorbate does not improve de novo BH 4 synthesis, nor is it a first-line defense against superoxide and peroxynitrite. 4 Thus a thorough understanding of the mechanisms involved in regulating the balance between the different redox forms of BH 4 , and the role of anti-oxidants in maintaining this balance, appears to be critical in designing rational therapeutic strategies to ameliorate endothelial dysfunction. This objective, however, will not be accomplished with the available analytical methods for BH 4 analysis. Indirect methodology such as that based on BH 4 oxidation to secondary products is complicated by fact that BH 4 is oxidized to generate several products. Clearly, this methodology prevents full identification and 
